Answers are grounded in this paper and cite their sources.
Objective. To assess technologies for measuring pH in organs and tissues, the relationship of local and systemic acid–base changes to disease, and their clinical translation into cancer diagnosis and treatment. Methods. A narrative synthesis combined targeted literature searches prioritizing studies published in 2016–2026, foundational sources, DOI-based bibliographic checks, and evidence extraction from primary reports. The core corpus reviewed through 1 November 2026 comprised 163 unique articles. Europe PMC records linked to PubMed, Crossref, publisher websites, and electronic scholarly sources were consulted; Consensus supported supplementary searches and identification of relevant source sections. Intracellular, extracellular, organellar, luminal, and biofluid pH were considered separately. A bounded systematic module examined human studies published from 1 January 2016 through 3 November 2026 that quantified tumor extracellular pH using exogenous CEST MRI. Results. Relevant full-text sections were verified for 90 core sources; reliance on abstracts, selected excerpts, or a preprint was recorded for the remainder. Electrochemical and optical sensors support continuous local measurements, whereas ³¹P MRS and CEST provide spatial information; their outputs are not interchangeable. Tumor acidosis is associated with metabolic, immune, and membrane processes. Clinical diagnostic studies remain limited by small samples, heterogeneous probe delivery, and inadequate independent reference measurements. Most pH-directed anticancer approaches remain preclinical or in early clinical trials. Correcting acid–base biomarkers can improve selected clinical outcomes, although survival benefits have not been consistent. The systematic module screened 83 unique records and included two clinical reports. These demonstrated the feasibility of pHₑ mapping and its promise as a diagnostic biomarker, but provided insufficient data to estimate patient-level sensitivity and specificity. Conclusion. The clinical value of pH depends on the biological compartment, its spatial and temporal variation, and measurement calibration. Priorities include compartment-specific monitoring, multicenter diagnostic validation against independent references, and trials linking biomarker changes to outcomes that matter to patients.
No takes yet. Share an insight, caveat, or question.
Askarov et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: